Assignee
FARON PHARMACEUTICALS OY
FI·14 granted patents·13 pending applications·20 citations·filing 2003–2023
Top patents by PatentIndex Score
27 records- 0179US11421279B2Method for determining patient's responsiveness to type 1 interferon treatment and use of type 1 interferon to treat patient having specified single nucleoide polymophismFARON PHARMACEUTICALS OY·Filed 2019·Granted Aug 23, 2022·2 cites·13 claims
- 0279US7910097B2Common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1) and uses thereofFARON PHARMACEUTICALS OY·Filed 2008·Granted Mar 22, 2011·5 cites·13 claims
- 0378US8975081B2Biomarker for monitoring development of diseases and assessing the efficacy of therapiesFARON PHARMACEUTICALS OY·Filed 2013·Granted Mar 10, 2015·2 cites·4 claims
- 0471US7534423B2Method for inducing an elevated level of adenosine in an individualFARON PHARMACEUTICALS OY·Filed 2004·Granted May 19, 2009·4 cites·10 claims
- 0569US7354577B2Common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1) and uses thereofFARON PHARMACEUTICALS OY·Filed 2003·Granted Apr 8, 2008·5 cites·7 claims
- 0666US10247730B2Method for determining acute respiratory distress syndrome (ARDS) related biomarkers, a method to monitor the development and treatment of ARDS in a patientFARON PHARMACEUTICALS OY·Filed 2014·Granted Apr 2, 2019·1 cites·15 claims
- 0765US10293030B2Lyophilised pharmaceutical formulation and its useFARON PHARMACEUTICALS OY·Filed 2016·Granted May 21, 2019·1 cites·23 claims
- 0862US2009269303A1Method for treating or preventing conditions by elevation of the adenosine level in an individualFARON PHARMACEUTICALS OY·Filed 2009·Application pending·0 cites
- 0959US2007191408A1Compositions useful especially for treatment or prevention of metabolic syndromeFARON PHARMACEUTICALS OY·Filed 2006·Application pending·0 cites
- 1058US12371486B2Humanized anti clever-1 antibodies and their useFARON PHARMACEUTICALS OY·Filed 2021·Granted Jul 29, 2025·0 cites·27 claims
- 1157US7727521B2Method of ameliorating multi-organ failure resulting from ischemic reperfusion injuryFARON PHARMACEUTICALS OY·Filed 2005·Granted Jun 1, 2010·0 cites·6 claims
- 1256US2023046617A1Method for promoting expansion of hematopoietic stem cells and agent for use in the methodFARON PHARMACEUTICALS OY·Filed 2021·Application pending·0 cites
- 1353US10526607B2Cell and therapeutical and diagnostical methods based thereonFARON PHARMACEUTICALS OY·Filed 2014·Granted Jan 7, 2020·0 cites·6 claims
- 1451US12472235B2Treatment of diseases with sequential administration of an agent capable of up-regulating CD73 and glucocorticoidsFARON PHARMACEUTICALS OY·Filed 2022·Granted Nov 18, 2025·0 cites·5 claims
- 1550US12553906B2Method for determining potency of therapeutic anti-clever-1 antibodyFARON PHARMACEUTICALS OY·Filed 2020·Granted Feb 17, 2026·0 cites·12 claims
- 1649US2025327806A1Method for identifying cancer patients that benefit from anti-clever-1 treatmentFARON PHARMACEUTICALS OY·Filed 2023·Application pending·0 cites
- 1749US2025383356A1Method for identifying cancer patients that benefit from anti-clever-1 treatmentFARON PHARMACEUTICALS OY·Filed 2023·Application pending·0 cites
- 1848US2025051438A1Method for using inflammatory markers to guide anti-clever-1 based cancer treatmentFARON PHARMACEUTICALS OY·Filed 2022·Application pending·0 cites
- 1946US11046761B2Humanized anti clever-1 antibodies and their useFARON PHARMACEUTICALS OY·Filed 2017·Granted Jun 29, 2021·0 cites·14 claims
- 2045US2022227858A1Controlling of immune activation by soluble clever-1FARON PHARMACEUTICALS OY·Filed 2022·Application pending·0 cites
- 2144US2023235046A1Stable anti-clever-1 antibody formulationFARON PHARMACEUTICALS OY·Filed 2022·Application pending·0 cites
- 2242US2023167173A1Treatment of diseases with clever-1 inhibition in combination with an interleukin inhibitorFARON PHARMACEUTICALS OY·Filed 2021·Application pending·0 cites
- 2338US2022404366A1Anti-clever-1 agents for controlling the expression of cell surface markers on leucocytes, and using these to guide anti-clever-1 based cancer treatmentFARON PHARMACEUTICALS OY·Filed 2020·Application pending·0 cites
- 2436US10884000B2Method of monitoring the efficacy of the anti-clever-1 therapy in cancerFARON PHARMACEUTICALS OY·Filed 2017·Granted Jan 5, 2021·0 cites·4 claims
- 2535US2021087264A1Anti-clever-1 agents for controlling lysosomal vatpase proton pumps to increase lysosomal ph-value and the cross-presentation of digested matterFARON PHARMACEUTICALS OY·Filed 2020·Application pending·0 cites
- 2634US2021371865A1Tlr9 agonists for use in downregulating clever-i expression on alternatively activated macrophagesFARON PHARMACEUTICALS OY·Filed 2019·Application pending·0 cites
- 2730US2021261657A1Treatment of cancer with clever-1 inhibition in combination with pd-1/pd-l1 inhibitorFARON PHARMACEUTICALS OY·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when FARON PHARMACEUTICALS OY files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →